6 trends tracked about this subject — the full history, oldest to newest below.
The FDA has approved an at-home subcutaneous starter dose for the Alzheimer's drug Leqembi, supported by real-world evidence of therapy benefits.
Biogen defends its anti-tau drug following a stock decline triggered by a recent Alzheimer's treatment readout.
Biogen shares fell following recent trial data for an Alzheimer's treatment.
An experimental Alzheimer's drug shows early promise while raising mixed questions and triggering a stock drop.
Biogen's experimental Alzheimer's drug diranersen has sparked industry-wide attention with new Phase 2 data presented at AAIC.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.